GLP1R and type 2 diabetes mellitus: The EXenatide Study of Cardiovascular Event Lowering (EXSCEL) was a randomized, placebo-controlled, global pragmatic clinical trial designed to assess the effect of subcutaneous once-weekly GLP-1 RA exenatide (EQW) 2 mg on cardiovascular outcomes in 14,752 participants with type 2 diabetes mellitus and a range of cardiovascular risk [11].